NCT02532153

The Impact of Ketamine on the Reward Circuitry of Suicidal Patients

The Impact of Ketamine on the Reward Circuitry of Suicidal Patients: An MRI Study

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

Every 40 seconds, someone in the world dies by suicide. There is a lack of effective and safe antisuicidal agents for preventing suicide attempts. This leads to the immense worldwide individual, financial, and societal burden of suicide-which is projected to rise in the coming decades-supporting the need for antisuicidal treatments. This treatment gap may be filled through understanding the neurobiology of suicide, which can guide the development of targeted antisuicidal treatments. Though some research has examined the neurobiology of suicidal ideation in the context of depression-implicating the orbital frontal cortex, anterior cingulate cortex, and striatum-the underlying pathophysiology and neurobiology of suicidal ideation as a separate construct from depression remains largely unknown. Therefore, the investigators propose to study the neurocircuitry of suicidal thoughts, regardless of whether or not depression is present.

Conditions

• Suicidal Ideation
• Suicide

Interventions

Type	Name	Description
DRUG	Ketamine Hydrochloride	Single open-label infusions

Timeline

• Start date: 2017-02-01
• Primary completion: 2017-02-01
• Completion: 2017-02-28
• First posted: 2015-08-25
• Last updated: 2017-03-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study